Business Wire

MD-IONQ

22.7.2024 14:01:26 CEST | Business Wire | Press release

Share
IonQ Unveils Accelerated Roadmap and New Technical Milestones to Propel Commercial Quantum Advantage Forward

IonQ (NYSE: IONQ), a leader in the quantum computing industry, recently unveiled expanded and accelerated 2025 technical milestones during an exclusive webinar hosted by CEO Peter Chapman, SVP of Engineering & Technology Dean Kassmann, and CMO Margaret Arakawa. IonQ established why it is the only quantum computing company designing and building best-in-class quantum computers that meet the requirements of performance, scalability, and enterprise-grade solutions that are critical for delivering unparalleled commercial advantage to customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722272052/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IonQ's three-pillar technology strategy to accelerate commercial advantage. (Graphic: Business Wire)

“It is imperative that we address performance, scale, and enterprise-grade quantum solutions simultaneously to achieve commercial advantage,” said Peter Chapman, President and CEO of IonQ. “Working to operationalize all three commercial advantage pillars is an industry-first that sets us apart. While other companies may hyperfocus on a single dimension, we focus on the complete picture, to ensure our quantum computing solutions are best-in-class and provide incomparable value to our customers.”

“Based on market demand, we’ve embarked on a path that no other commercial quantum computing company is taking, and we are committed to accelerating our quantum computing strategy as demonstrated by these ambitious goals,” said Dean Kassmann, SVP of Engineering & Technology at IonQ. “Our unique approach combines high performance single core operation, multi-core parallelism, modularity, photonic interconnects, novel technology, and systems engineering to deliver highly performant, scalable, and enterprise-grade quantum computers that drive meaningful advancements across various industries.”

Performance: Driving Efficiency and Unparalleled Flexibility

Performance improvements are core to IonQ’s technical roadmap, and the path toward meeting IonQ’s aggressive performance targets is clear. Native gate fidelity, architectural design decisions, and error correction will serve as levers to achieve these goals. IonQ is driving to improve native two-qubit gate performance to greater than three 9’s (>99.9%) in 2025, with further gains – fueled by the move to barium qubits – expected the following year. Performance improvements are also expected from highly efficient realizations of quantum algorithms that are enabled by IonQ’s low-shuttling, high-connectivity architectures. Lastly, the combination of high native gate fidelity and high connectivity provides unparalleled flexibility for implementing error correction and reducing time to solution. With this updated quantum architecture, IonQ expects to reach five 9’s (99.999%) in logical two-qubit gate fidelity by the end of 2025, opening up new application performance capabilities.

Scale: Architecture that Enables Expansive Growth

IonQ is pursuing scale in tandem with performance. IonQ’s north star is scalability at high performance, and modularity is a critical component of this strategy. IonQ’s approach to scale relies on making engineering and architectural decisions that support performance at large qubit counts. In addition, IonQ’s strategy for scaling takes advantage of multicore operation and photonically interconnected systems. Connecting multiple QPUs and quantum systems with photonic interconnects will enable IonQ to target 1000s of physical qubits in the future. These higher qubit counts will unlock new problem spaces and enable developers and researchers to tackle increasingly complex problems.

Enterprise-Grade: Meeting Real-World Needs

IonQ’s enterprise-grade approach readies its quantum systems for deployment across various sectors, focusing on manufacturability, deployability, and customer applications at scale. IonQ has already formed successful partnerships with organizations like the Naval Research Laboratory (NRL), Airbus, and Deutsches Elektronen-Synchrotron (DESY) – an internationally renowned center of fundamental research – as they focus on optimization problems and quantum chemistry and other important real-world applications. Additionally, IonQ is exploring a growing number of quantum algorithms across fields such as AI, financial services, and cybersecurity, reinforcing its commitment to real-world quantum technology applications.

Currently, IonQ operates two quantum data centers—one at its headquarters in College Park, Maryland, and another in Seattle, Washington, which the company opened earlier this year. Later this year, IonQ will expand its footprint by bringing its quantum data center in Basel, Switzerland, online. All of these locations are dedicated to supporting the needs of IonQ’s customers.

This momentum underscores IonQ's leadership in the quantum computing industry and robust industry demand. IonQ's enterprise strategy and expanding infrastructure highlight its dedication to unlocking commercial advantage by collaborating with industry leaders and making cutting-edge, well-balanced, quantum technology available ahead of schedule.

To learn more about IonQ and its latest system news and business developments, visit https://ionq.com/.

About IonQ

IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “accelerate,” “advance,” “dedicate,” “deploy,” “drive,” “enable,” “expand,” “expect,” “improve,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial advantage in the future, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, the effect of increased availability of customer support functions and enterprise-grade solutions, IonQ’s quantum computing capabilities and plans, access to IonQ’s quantum computers, increases in algorithmic qubit achievement, and the scalability, performance, and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates, including development of competing technologies; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722272052/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye